Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.59 |
| ▸ | CTSS | P25774 | 7/20 | 0.55 |
| ▸ | CTSK | P43235 | 6/20 | 0.55 |
| ▸ | CTSB | P07858 | 4/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.51 |
| ▸ | ITGAV | P06756 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054782 | 1.00 | ACE (0.59) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL10054648 | 0.93 | KLK5 (0.57) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL8072127 | 0.88 | ACE (0.60) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL8072132 | 0.88 | ACE (0.60) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL11973513 | 0.87 | ITGB3 (0.59) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL11973516 | 0.87 | ITGB3 (0.59) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL8070828 | 0.86 | CTSS (0.59) | ACECTSSCTSKCTSBPPARA | |
| SCHEMBL30441251 | 0.85 | ACE (0.52) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL21683145 | 0.85 | ACE (0.52) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL21683143 | 0.85 | ACE (0.52) | ACECTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921319-B2 | Serine protease inhibitors | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| US-20130267467-A1 | SERINE PROTEASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-10-10 | — | — | US | disclosed |
| WO-2012004678-A2 | SERINE PROTEASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267467-A1 | SERINE PROTEASE INHIBITORS | SERPINE1, KLKB1, SERPINC1 | ACE 158/4885CTSS 216/4885CTSK 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.